| scholarly article | Q13442814 |
| P50 | author | Jose M Valdivielso | Q41584735 |
| Eva Parisi | Q59164202 | ||
| P2093 | author name string | Elvira Fernandez | |
| Sara Panizo | |||
| Anna Cardús | |||
| P2860 | cites work | Abdominal aortic calcific deposits are an important predictor of vascular morbidity and mortality | Q43546639 |
| P433 | issue | 6 | |
| P921 | main subject | vitamin | Q34956 |
| vitamin D | Q175621 | ||
| P304 | page(s) | 860-866 | |
| P577 | publication date | 2007-06-01 | |
| P1433 | published in | Journal of Bone and Mineral Research | Q15750941 |
| P1476 | title | Differential effects of vitamin D analogs on vascular calcification | |
| P478 | volume | 22 |
| Q46384854 | 25-Hydroxyvitamin D3, arterial calcifications and cardiovascular risk markers in haemodialysis patients |
| Q52413006 | A Novel Mechanism for Atherosclerotic Calcification: Potential Resolution of the Oxidation Paradox. |
| Q37558961 | A new role for vitamin D receptor activation in chronic kidney disease |
| Q34683694 | Active vitamin D and accelerated progression of aortic stiffness in hemodialysis patients: a longitudinal observational study. |
| Q27002431 | Are there ways to attenuate arterial calcification and improve cardiovascular outcomes in chronic kidney disease? |
| Q55024096 | Association between Dietary Intake and Coronary Artery Calcification in Non-Dialysis Chronic Kidney Disease: The PROGREDIR Study. |
| Q37781455 | Calcific Uremic Arteriolopathy: Contemporary Pharmacotherapy |
| Q87041760 | Chapter 4.1: Treatment of CKD-MBD targeted at lowering high serum phosphorus and maintaining serum calcium |
| Q36316104 | Chondro/osteoblastic and cardiovascular gene modulation in human artery smooth muscle cells that calcify in the presence of phosphate and calcitriol or paricalcitol |
| Q46470848 | Differential effects of vitamin D receptor activators on aortic calcification and pulse wave velocity in uraemic rats |
| Q37594768 | Differential modulation of RANKL isoforms by human osteoarthritic subchondral bone osteoblasts: influence of osteotropic factors |
| Q53610668 | Effect of cholecalciferol replacement on vascular calcification and left ventricular mass index in dialysis patients. |
| Q54642763 | Effect of combination therapy with angiotensin receptor blocker and 1,25-dihydroxyvitamin D(3) in type 2 diabetic nephropathy in KK-A(y)/Ta mice. |
| Q36255981 | Effects of the Administration of 25(OH) Vitamin D3 in an Experimental Model of Chronic Kidney Disease in Animals Null for 1-Alpha-Hydroxylase |
| Q37123402 | Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism |
| Q50077724 | Etelcalcetide, A Novel Calcimimetic, Prevents Vascular Calcification in A Rat Model of Renal Insufficiency with Secondary Hyperparathyroidism |
| Q54426389 | Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy. |
| Q46228204 | Hyperphosphatemia and hyperparathyroidism in incident chronic kidney disease patients |
| Q27320886 | Impaired Vitamin D Signaling in Endothelial Cell Leads to an Enhanced Leukocyte-Endothelium Interplay: Implications for Atherosclerosis Development |
| Q38828618 | Integral pharmacological management of bone mineral disorders in chronic kidney disease (part II): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification |
| Q39740048 | Integrated backscatter for the in vivo quantification of supraphysiological vitamin D(3)-induced cardiovascular calcifications in rats |
| Q34777112 | Interdependence of cardiac iron and calcium in a murine model of iron overload |
| Q37547201 | Management of secondary hyperparathyroidism in the elderly patient with chronic kidney disease. |
| Q36624625 | MicroRNAs 29b, 133b, and 211 Regulate Vascular Smooth Muscle Calcification Mediated by High Phosphorus |
| Q42727533 | Mineral and bone disorders in chronic kidney disease and end-stage renal disease patients: new insights into vitamin D receptor activation |
| Q37596614 | Modulation of OPG, RANK and RANKL by human chondrocytes and their implication during osteoarthritis |
| Q37691299 | New therapies: calcimimetics, phosphate binders and vitamin D receptor activators. |
| Q36947028 | Nonclassical aspects of differential vitamin D receptor activation: implications for survival in patients with chronic kidney disease |
| Q38028534 | Parathyroid gland regulation: contribution of the in vivo and in vitro models. |
| Q36504284 | Pharmacological induction of ferritin prevents osteoblastic transformation of smooth muscle cells |
| Q37948105 | Pharmacotherapy of chronic kidney disease and mineral bone disorder. |
| Q37492019 | Phosphate: an old bone molecule but new cardiovascular risk factor |
| Q91725679 | Phosphorus Consumption Within 1 Hour Prior to Blood Work and Associated Serum Levels of Phosphate, Calcium, and PTH in Adult Patients Receiving Hemodialysis Treatment |
| Q37376932 | Potential for vitamin D receptor agonists in the treatment of cardiovascular disease |
| Q28271069 | Relation of oral 1alpha-hydroxy vitamin D3 to the progression of aortic arch calcification in hemodialysis patients |
| Q90631576 | Research Models for Studying Vascular Calcification |
| Q37226885 | Role of vitamin D in chronic kidney disease |
| Q37335065 | Role of vitamin D receptor activators on cardiovascular risk |
| Q34993353 | Runx2-upregulated receptor activator of nuclear factor κB ligand in calcifying smooth muscle cells promotes migration and osteoclastic differentiation of macrophages. |
| Q40319543 | Successful use of low-dose intravenous paricalcitol in the treatment of severe secondary hyperparathyroidism in a haemodialysis patient. |
| Q54350108 | The effect of vitamin D derivatives on vascular calcification associated with inflammation. |
| Q36613869 | The influence of selective vitamin D receptor activator paricalcitol on cardiovascular system and cardiorenal protection |
| Q38599585 | Treatment with pyrophosphate inhibits uremic vascular calcification |
| Q44261849 | VDRAs versus calcimimetics: better safe than sorry? |
| Q50226760 | Vascular Calcification Induced by Chronic Kidney Disease Is Mediated by an Increase of 1α-Hydroxylase Expression in Vascular Smooth Muscle Cells. |
| Q48336125 | Vascular calcification and 25-hydroxyvitamin D levels in non-dialysis patients with chronic kidney disease stages 4 and 5 |
| Q37195354 | Vascular calcification in chronic kidney disease: Pathogenesis and clinical implication |
| Q37279081 | Vitamin D and Clinical Outcomes in Dialysis |
| Q42092825 | Vitamin D and kidney disease |
| Q28284363 | Vitamin D and osteogenic differentiation in the artery wall |
| Q38152318 | Vitamin D and the cardiovascular system: an overview of the recent literature. |
| Q37892311 | Vitamin D and vascular calcification in chronic kidney disease |
| Q54956836 | Vitamin D in Vascular Calcification: A Double-Edged Sword? |
| Q38803449 | Vitamin D in patients with chronic kidney disease: a position statement of the Working Group "Trace Elements and Mineral Metabolism" of the Italian Society of Nephrology |
| Q33748607 | Vitamin D induces increased systolic arterial pressure via vascular reactivity and mechanical properties |
| Q35094837 | Vitamin D metabolism, mechanism of action, and clinical applications |
| Q38069143 | Vitamin D receptor activation and cardiovascular disease |
| Q37089710 | Vitamin D receptor activation and survival in chronic kidney disease. |
| Q49061065 | Vitamin D receptor activation, left ventricular hypertrophy and myocardial fibrosis. |
| Q36438261 | Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet |
| Q34997739 | Vitamin D supplementation and mortality risk in chronic kidney disease: a meta-analysis of 20 observational studies |
| Q38094034 | Vitamin D supplementation in older adults: searching for specific guidelines in nursing homes |
| Q37737597 | Vitamin D, chronic kidney disease and survival: a pluripotent hormone or just another bone drug? |
| Q37231813 | What is the optimal level of vitamin D in non-dialysis chronic kidney disease population? |
Search more.